Quantcast
Last updated on April 16, 2014 at 10:23 EDT

Latest Stent Stories

2013-05-26 08:20:18

SINGAPORE, May 26, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced the completion of its acquisition of substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions. The deal consideration is approximately...

2013-05-24 08:23:18

BOSTON and TEL AVIV, Israel, May 24, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that Alan Milinazzo, the Company's President and Chief Executive Officer, and Craig Shore, the Company's Chief Financial Officer, will participate in the Benchmark Company, LLC One-on-One Investor Conference on Thursday May 30, 2013 at The Pfister Hotel, 424 East Wisconsin Ave., Milwaukee, WI. The...

2013-05-23 08:26:36

Company to Host Conference Call Today at 8:00am ET, 2:00pm CET PARIS, May 23, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial...

2013-05-22 08:29:49

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the...

2013-05-21 08:28:47

- XIENCE Xpedition(TM) 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition(TM) 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and...

2013-05-21 04:21:05

WIESBADEN, Germany, May 21, 2013 /PRNewswire/ -- Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") today announced that it has enforced the seizure of over 190 stent systems from Boston Scientific Corporation (NYSE: BSX) in connection with its patent infringement proceedings in the Dusseldorf Regional Court. The products were found on May 15, 2013, at the premises of Boston Scientific Medizintechnik GmbH in Ratingen...

2013-05-21 04:20:47

PARIS, May 21, 2013 /PRNewswire/ -- The delayed healing of the coronary artery following physicians' use of drug eluting stents (DES), which increases patients' risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris. In the online survey of 141 interventional cardiologists in Belgium, China, Denmark, Germany, Italy, Malaysia, The Netherlands, Singapore and the United Kingdom, participants...

2013-05-20 23:19:09

Allegheny General Hospital (AGH) in Pittsburgh has been selected to join the ABSORB III clinical trial, a multi-center international study exploring a unique bioresorbable vascular scaffold (BVS), a small mesh tube that is designed to open a blocked artery and then fully dissolve over time, leaving the vessel free of a permanent metallic implant. The FDA-approved study of the drug-eluting AbsorbTM BVS, made by healthcare company Abbott, is expected to enroll approximately 2,250 patients...

2013-05-20 04:20:50

Results of Randomized JACK-EPC Trial Published in Minerva Cardioangiologica HONG KONG, May 20, 2013 /PRNewswire/ -- OrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva...

2013-05-17 08:24:19

NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24 clinical presentations will feature new data and analyses on products including the Boston Scientific SpyGlass® Direct Visualization System, WallFlex® Biliary RX Stent System and Expect® 19 Flex Endoscopic Ultrasound Aspiration Needle. "The insights and data included in these...


Latest Stent Reference Libraries

Interventional Radiology
2013-03-04 16:18:42

Interventional radiology (IR) is a special sub-operation under general radiology. It is used to find, diagnose and treat a disease in almost every body system. The process of interventional radiology is very noninvasive to help with the recovery and outcome of the procedure. It utilizes x-rays, CT, ultrasound, MRI, and other modes of imaging in order to direct tools in the body as well as a variety of catheters, narrow tubes, so that incisions can be minimalized. How it is Performed...

More Articles (1 articles) »